


Sheet 1 of 1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				ATTY. DOCKET NO.: IN01344		APPLICATION NO.: 09/981,215	
				APPLICANT: JANICE K. ALBRECHT			
				FILING DATE: 10/16/2001		GROUP: 1648	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AF						
	AG						
	AH						
	AI						
	AJ						
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
SF	AK	Reichard, et al., "Randomized double-blind, placebo-controlled trial of interferon α -2b without ribavirin for chronic hepatitis C", The Lancet, 1998, Vol. 351: 83-87.					
	AL	Poynard, T., et al., "Randomized trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus", The Lancet, 1998, Vol. 352: 1426-1432.					
	AM	McHutchinson, et al., "Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C", N. Eng. J. Med., 1998, Vol. 339: 1485-1492.					
	AN	Davis, et al., "Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C", N. Engl. J. Med., 1998, Vol. 339: 1493-1499.					
SF	AO	Manns, et al., "Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial", The Lancet, 2001, Vol. 358: 958-965.					
	AP						
EXAMINER 				DATE CONSIDERED 4/15/4			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							